Influx Healthtech Limited
Fundamental Score
Influx Healthtech Limited Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of INFLUX across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (45.38%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (60.16%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Robust Profit Growth (78.11%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (38.91%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Balanced Promoter Holding (73.53%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 8.66%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Financial Statements
Comprehensive financial data for Influx Healthtech Limited
About INFLUX
Company Details
INFLUX Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Influx Healthtech Limited (INFLUX)?
As of 30 Jan 2026, 01:41 pm IST, Influx Healthtech Limited (INFLUX) is currently trading at ₹214.20. The stock has a market capitalization of ₹526.79 (Cr).
Is INFLUX share price Overvalued or Undervalued?
INFLUX is currently trading at a P/E ratio of 29.83x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Influx Healthtech Limited share price?
Key factors influencing INFLUX's price include its quarterly earnings growth (Sales Growth: 38.91%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Influx Healthtech Limited a good stock for long-term investment?
Influx Healthtech Limited shows a 5-year Profit Growth of N/A% and an ROE of 45.38%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Influx Healthtech Limited compare with its industry peers?
Influx Healthtech Limited competes with major peers in the Pharmaceuticals. Investors should compare INFLUX's P/E of 29.83x and ROE of 45.38% against the industry averages to determine its competitive standing.
What is the P/E ratio of INFLUX and what does it mean?
INFLUX has a P/E ratio of 29.83x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹30 for every ₹1 of annual earnings.
How is INFLUX performing according to Bull Run's analysis?
INFLUX has a Bull Run fundamental score of 45.9/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does INFLUX belong to?
INFLUX operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Influx Healthtech Limited.
What is Return on Equity (ROE) and why is it important for INFLUX?
INFLUX has an ROE of 45.38%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Influx Healthtech Limited generates profits from shareholders' equity.
How is INFLUX's debt-to-equity ratio and what does it indicate?
INFLUX has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is INFLUX's dividend yield and is it a good dividend stock?
INFLUX offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has INFLUX grown over the past 5 years?
INFLUX has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in INFLUX and why does it matter?
Promoters hold 73.53% of INFLUX shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is INFLUX's market capitalization category?
INFLUX has a market capitalization of ₹527 crores, placing it in the Small-cap category.
How volatile is INFLUX stock?
INFLUX has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for INFLUX?
INFLUX has a 52-week high of ₹N/A and low of ₹N/A.
What is INFLUX's operating profit margin trend?
INFLUX has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is INFLUX's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 38.91% and YoY Profit Growth of 78.11%.
What is the institutional holding pattern in INFLUX?
INFLUX has FII holding of 1.83% and DII holding of 6.83%. Significant institutional holding often suggests professional confidence in the stock.